GSK gets bad press in U.S., Argentina




An increasing number of drug studies are happening in emerging markets in an attempt to cut costs. Some say the rationale also includes the fact that many patients in these poorer countries are not on any conflicting medications. Critics allege companies are conducting trials countries where there are fewer regulations to protect patients and few resources to enforce the regulations that are in place. To date, at least 12 babies have died in the GSK trial in Argentina over the last year.


– read the ABC News story
– here’s the Pharmalot blog entry 


Related Articles:
Investigators: Most data on drugs never available
Emerging markets drive global growth
GlaxoSmithKline – Top 15 R&D Budgets


Leave a Reply